A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
收藏NIAID Data Ecosystem2026-03-11 收录
官方服务：
资源简介：
ATRC-101-A01 is a Phase 1b, open-label dose escalation and expansion trial of ATRC-101, an engineered fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally occurring human antibody. The safety, tolerability, PK, and biological activity of ATRC-101 will be characterized when administered every two weeks (Q2W) or every 3 weeks (Q3W) as a monotherapy or in combination with other anticancer agents.
创建时间：
2020-02-15
